Alcidion Group Ltd (ASX: ALC) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Alcidion Group Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $79.21 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 1.34 billion
Earnings per share -0.004
Dividend per share N/A
Year To Date Return -28.00%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

  • Alcidion Group Ltd (ASX: ALC)
    Latest News

    A woman holds her hands to the side of her face as she sits back in shock at something she is reading or seeing on her computer screen.
    Healthcare Shares

    Why is the Alcidion share price crashing 27% to a 52-week low?

    This healthcare technology company is having a day to forget on Wednesday.

    Read more »

    Small girl giving a fist bump with a piggy bank in front of her.
    Broker Notes

    400% organic growth in 3 years: The ASX small-cap Cyan is pumped about

    Smaller stocks have been punished the past couple of years, but recent weeks have shown the start of a recovery.

    Read more »

    an attractive young woman with sad eyes holds a red paper love heart over her mouth as though she has been unlucky in love.

    An unloved ASX stock I'm considering buying with $5,000 in August

    This software maker has been punished by the market over the past couple of years, but it's now gone too…

    Read more »

    A man in his 30s holds his laptop and operates it with his other hand as he has a look of pleasant surprise on his face as though he is learning something new or finding hidden value in something on the screen.
    Earnings Results

    Alcidion share price charges 9% ahead on record quarter

    The company's share price has suffered throughout 2023, but the business fundamentals of Alcidion are moving in the right direction.

    Read more »

    Two kids in superhero capes.
    Small Cap Shares

    'Upside surprise': 2 small-cap ASX shares ready to break out

    The seas are rough, but Cyan's Dean Fergie reminds investors you need to hold on tight if you still believe…

    Read more »

    A cool young man walking in a laneway holding a takeaway coffee in one hand and his phone in the other reacts with surprise as he reads the latest news on his mobile phone
    Broker Notes

    Leading brokers name 3 ASX shares to buy today

    Analysts believe that now could be the time to add these shares to your portfolio...

    Read more »

    two children squat down in the dirt with gardening tools and a watering can wearing denim overalls and smiling very sweetly.
    Growth Shares

    ASX shares: Invest in these 2 stocks for a legit chance at $1 million

    The key to achieving a $1 million portfolio is finding big compounding potential in small places...

    Read more »

    A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
    Share Market News

    3 ASX All Ordinaries shares getting hammered on quarterly updates

    Monday has not been kind to these ASX All Ords shares...

    Read more »

    Two men cheering at laptop

    Skin in the game: The ASX share in my portfolio I'm most excited about

    Our Foolish writers spill the tea on the shares they own and have the highest hopes for.

    Read more »

    three children wearing superhero costumes, complete with masks, pose with hands on hips wearing capes and sneakers on a running track.
    Small Cap Shares

    3 battered small-cap ASX shares we're still backing: expert

    Smaller businesses saw their valuations tumble in a troubled year like 2022, but will likely rocket up higher and faster…

    Read more »

    A man clenches his fists in excitement as gold coins fall from the sky.
    Share Market News

    Top fund manager thinks ASX could start to move decisively higher, potentially sooner than you might be expecting

    Two ASX small cap stocks with material upside potential.

    Read more »

    A happy woman holding an umbrella in front of a rainbow.
    Best Shares

    Top ASX shares to buy in September 2022

    These are the stocks our Foolish writers think could be set to blossom in spring.

    Read more »

    Frequently Asked Questions

    No, Alcidion does not pay dividends at this time.

    Alcidion listed on the ASX on 24 June 2011.

    ALC ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

    About Alcidion Group Ltd

    Alcidion Group Ltd (ASX: ALC) is a provider of intelligent informatics software for the healthcare sector.

    The company builds, sells, delivers, runs, and supports solutions for healthcare providers. These include clinical, analytical, managerial, and administrative systems.

    Its products include its Miya suite, a Fast Healthcare Interoperability Resources (FHIR) system that allows comprehensive healthcare data to be exchanged between different computer systems.  Other products include Smartpage and Patientrack software.

    Alcidion derives the majority of its revenue from its Australia/New Zealand segment and also has a presence in the United Kingdom.

    ALC Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    15 Jul 2024 $0.05 $0.00 0.00% 1,143,711 $0.05 $0.06 $0.05
    12 Jul 2024 $0.05 $0.00 0.00% 2,025,931 $0.05 $0.05 $0.05
    11 Jul 2024 $0.05 $0.00 0.00% 1,529,759 $0.05 $0.05 $0.05
    10 Jul 2024 $0.05 $0.00 0.00% 512,768 $0.05 $0.05 $0.05
    09 Jul 2024 $0.05 $0.00 0.00% 101,600 $0.05 $0.05 $0.05
    08 Jul 2024 $0.05 $0.00 0.00% 91,759 $0.05 $0.05 $0.05
    05 Jul 2024 $0.05 $0.00 0.00% 582,119 $0.05 $0.05 $0.05
    04 Jul 2024 $0.05 $0.00 0.00% 2,483,479 $0.05 $0.06 $0.05
    03 Jul 2024 $0.05 $0.00 0.00% 123,085 $0.05 $0.05 $0.05
    02 Jul 2024 $0.05 $0.00 0.00% 43,019 $0.05 $0.05 $0.05
    01 Jul 2024 $0.05 $0.00 0.00% 524,121 $0.05 $0.05 $0.05
    28 Jun 2024 $0.05 $0.00 0.00% 1,116,977 $0.05 $0.05 $0.05
    27 Jun 2024 $0.05 $0.00 0.00% 880,571 $0.05 $0.05 $0.05
    26 Jun 2024 $0.05 $0.00 0.00% 1,665,792 $0.05 $0.05 $0.05
    25 Jun 2024 $0.05 $0.00 0.00% 1,306,418 $0.05 $0.05 $0.05
    24 Jun 2024 $0.05 $0.00 0.00% 1,493,726 $0.05 $0.05 $0.05
    21 Jun 2024 $0.05 $0.00 0.00% 2,412,891 $0.05 $0.05 $0.05
    20 Jun 2024 $0.05 $0.00 0.00% 1,042,326 $0.05 $0.05 $0.05
    19 Jun 2024 $0.05 $0.00 0.00% 878,670 $0.05 $0.05 $0.05
    18 Jun 2024 $0.05 $0.00 0.00% 836,418 $0.05 $0.05 $0.05

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    26 Apr 2024 Daniel Sharp Transfer 800,000 $44,000
    Off-market transfer. Assuming off market transfer of shares
    26 Apr 2024 Daniel Sharp Buy 250,000 $13,070
    On-market trade.
    26 Apr 2024 Daniel Sharp Transfer 800,000 $44,000
    Off-market transfer. Assuming off market transfer of shares
    23 Apr 2024 Katrina (Kate) Doyle (Quirke) Buy 1,000,000 $46,671
    On-market trade.
    23 Apr 2024 Katrina (Kate) Doyle (Quirke) Transfer 1,000,000 $46,000
    Off-market transfer. Assuming off market transfer of shares
    23 Apr 2024 Katrina (Kate) Doyle (Quirke) Transfer 1,000,000 $46,000
    Off-market transfer. Assuming off market transfer of shares
    05 Sep 2023 Victoria Weekes Buy 100,000 $12,000
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Ms Rebecca Wilson Non-Executive DirectorNon-Executive Chairman Jul 2017
    Ms Wilson is an experienced company director and Board advisor in Australia, UK and US and has more than 25 years of experience working within the healthcare, technology and life science sectors. She provides advice on complex stakeholder communication, issues management, investor and corporate relations, and business strategy to private and public companies, corporations, governments, and asset managers. She has mature governance and risk management experience.
    Mr Simon Chamberlain Non-Executive Director Jul 2019
    Mr Chamberlain is an accomplished executive and business leader, with more than 20 years experience in executive roles at companies including Experian (LON: EXPN), Medibank Private (ASX: MPL), Qantas (ASX:QAN) and MedAdvisor (ASX:MDR). He is currently the Chief Revenue Officer at the high-growth, techenabled residential services business, Detector Inspector, where he runs the sales, marketing, support and strategy functions. Simon has a proven track record for strategic success and commercial growth across a range of industries and markets. Simon led Qantas entrance into the online hotels business, establishing a profitable, high growth new division. At Medibank, Simon had responsibility across customer channels, data and customer experience. Gaining a better understanding of the complex challenges facing the wider health system led to Simons role leading strategy for MedAdvisor, where he supported the global expansion of its health technology business. Simon brings a valuable international perspective and global network to the Alcidion Board, holding executive roles across the US and the UK, where he was a key part of the executive team that sold the Australian start-up, Hitwise, to Experian in 2007. He is also a member of risk committee.
    Ms Victoria Weekes Non-Executive Director Sep 2021
    Ms Weekes is an non-executive director with experience across a diverse range of industries built on a successful executive career in investment markets and financial services. Victorias 30 years of experience in the finance and banking sector includes Csuite roles as a Managing Director at Citigroup and Executive General Manager at Westpac. As the immediate past Chair of the Sydney Local Health District, Victoria has a deep understanding of the healthcare sector where she served as Chair of its Education & Research Committee and Deputy Chair. Recognised for her specialist expertise in risk management and regulation having led organisations through strategic issue management and transformational change, Victoria is Deputy Chair of the ASIC Markets Disciplinary Panel, immediate past Chair of the NSW Treasury Audit & Risk Committee and President of the Financial Services Institute of Australasia (FINSIA). Until recently Victoria was the Deputy Chair of St George Community Housing, NSWs largest non-government community and affordable housing provider and a member of the Council of the State Library of NSW. She is the chairman of risk committee.
    Ms Katrina (Kate) Elizabeth Doyle (Quirke) Chief Executive OfficerExecutive DirectorManaging Director Jul 2018
    Ms Doyle has been CEO of Alcidion since 2018, prior to which she was CEO of MKM Health until it was acquired by Alcidion. She has been involved in large systems procurements and implementations of healthcare information technology across Australia, United Kingdom, New Zealand and Southeast Asia. Her background involves holding leading management roles at some of the largest healthcare software firms where she has had an impact on strategic product direction across
    the health sector and believes astute application of information technology will support the transformation of healthcare delivery worldwide.
    Mr Daniel Sharp Non-Executive Director Sep 2021
    Originally commencing his career as a lawyer,Mr Sharp has over 25 years senior executive experience in investment banking and corporate finance. From 2012-2020, Daniel was an Executive Director of Corporate Finance at Canaccord Genuity where he led dozens of equity capital market transactions and corporate finance advisory projects across the healthcare, life sciences, technologies, financial services and general industrials sectors. Prior to his executive role at Canaccord, Daniel headed the corporate finance division at two of Australias leading independent Investment Banking/Stockbroking firms. Daniel has managed the IPOs, capital raisings and corporate advisory activities for many successful ASX listed companies in the healthcare, technologies and general industrials sectors. He is closely connected to strong networks of institutional, family office and high net worth investors both in Australia and overseas. he is also a member of risk committee.
    Ms Melanie Jaye Leydin Company Secretary Mar 2019
    Melanie Jaye Leydin Company Secretary

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    J P Morgan Nominees Australia Pty Limited 139,803,795 11.02%
    Mr Malcolm Pradhan 134,582,403 10.61%
    Mr Raymond Howard Blight 75,801,020 5.98%
    Citicorp Nominees Pty Limited 58,449,895 4.61%
    Rewmicman Pty Ltd <Smallman Family A/C> 29,810,441 2.35%
    Mrs Katrina Elizabeth Doyle 27,793,199 2.19%
    Caledonia Nominees Pty Ltd <Caledonia A/C> 19,976,377 1.58%
    MNMD Pty Ltd <Quirke Super Fund A/C> 18,668,086 1.47%
    Rangiora-London Pty Limited <Rangiora-London A/C> 9,800,000 0.77%
    Sandhurst Trustees Ltd <Cyan C3G Fund A/C> 9,469,114 0.75%
    Bnp Paribas Noms Pty Ltd <Drp> 9,129,104 0.72%
    Hsbc Custody Nominees (Australia) Limited 8,651,688 0.68%
    Mr Dean Anthony Mackenzie 8,270,080 0.65%
    Mr Paul John Van Dyk 7,277,866 0.57%
    Isle Of Wight Pty Limited <Mackinnon Family A/C> 6,980,867 0.55%
    Emerald Shares Pty Limited <Emerald Unit A/C> 6,850,000 0.54%
    Hudson Retirement Pty Ltd <Seagulls Super A/C> 6,524,244 0.51%
    Mr Vivek Ramakrishnan + Miss Nisha Srinivasan 6,033,121 0.48%
    Superhero Securities Limited <Client A/C> 5,602,157 0.44%
    Beale & Co Pty Ltd 5,066,134 0.40%